Unbiased AI-powered news
1 stories related to this topic, newest first.
Substrate placeholder — needs reviewNeurocrine Biosciences has entered an agreement to purchase Soleno Therapeutics for $2.9 billion in cash. The acquisition aims to broaden Neurocrine's portfolio in treatments for rare genetic disorders. Soleno's lead product, DCCR, targets Prader-Willi syndrome, a rare condition…